Upfront PSMA PET imaging detects hidden metastases in early prostate cancer, altering treatment plans in up to one-third of ...

President Joe Biden recently gave an update on his treatment for metastatic prostate cancer. A urologist explains ways to ...

The FDA has expanded Pluvicto’s approval, allowing its use earlier in treatment for PSMA‑positive metastatic ...

UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against ...

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a ...

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

Scientists develop an antibody that slowed advanced prostate cancer and blocked its spread in early laboratory studies.

PSMA-PET scans detected metastatic disease in 46% of patients, indicating understaging by conventional imaging in high-risk nonmetastatic hormone-sensitive prostate cancer. The study involved 182 ...

A study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population; PSMAddition ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...